Mesoridazine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Severe schizophrenia; Resistant schizophrenia Initial: 25-50 mg 3 times/day, up to 100-400 mg/day based on response. IM Severe schizophrenia; Resistant schizophrenia Initial: 25 mg. Repeat after 30-60 mins if needed; up to 200 mg/day if needed.
Dosage Details
Intramuscular
Resistant schizophrenia, Severe schizophrenia
Adult: Initially, 25 mg. Repeat after 30-60 min if necessary; up to 200 mg daily has been given.

Oral
Resistant schizophrenia, Severe schizophrenia
Adult: Initially, 25-50 mg tid. May adjust dose to 100-400 mg according to response.
Reconstitution
Oral:
Dilute oral concentrate just prior to admin with distilled water, acidified tap water, orange or grape juice. Do not prepare and store bulk dilutions.
Incompatibility
Oral:
Do not mix oral solutions of mesoridazine and lithium.
Contraindications
Severe CNS depression and coma; prolonged QT interval (>450 msec), including congenital prolongation; history of arrhythmias. Lactation.
Special Precautions
Admin to patients only if baseline QTc <450 msec. Discontinue if QTc interval >500 msec. Monitor potassium levels. CNS depression; Parkinson's disease; haemodynamic instability; bone marrow suppression; predisposition to seizures; subcortical brain damage; severe cardiac, hepatic, renal or respiratory disease; patients at risk of pneumonia (e.g. Alzheimer's disease); breast cancer or other prolactin-dependent tumours. May alter temperature regulation or mask toxicity of other drugs. Patients at risk of orthostatic hypotension; cerebrovascular disease, CVD. Decreased GI motility, urinary retention, benign prostatic hyperplasia, xerostomia or visual problems. Narrow-angle glaucoma and myasthenia gravis. Pregnancy.
Adverse Reactions
Hypotension, orthostatic hypotension, tachycardia, cardiac arrhythmias, sinus tachycardia; sedation, drowsiness, restlessness, anxiety, extrapyramidal symptoms, pseudoparkinsonian signs, tardive dyskinesia, neuroleptic malignant syndrome, seizures, altered central temperature regulation, akathisia, dystonias, dizziness, hyperthermia; hypersensitivity reactions; amenorrhoea, galactorrhoea, gynaecomastia, syndrome of inappropriate antidiuretic hormone; GI upset, xerostomia, constipation, wt gain; urinary retention, impotence; agranulocytosis, leukopenia, thrombocytopenia, haemolysis, eosinophilia; cholestatic jaundice; trismus; retinal pigmentation, nystagmus, blurred vision; nasal congestion; decreased diaphoresis, SLE.
Overdosage
Symptoms: Involuntary muscle movements, haematological disturbances (e.g. agranulocytosis, leukopenia), arrhythmias, coma, deep sleep, ejaculatory disturbances, enuresis, extrapyramidal reaction, galactorrhoea, gynaecomastia, hypotension, impotence, neuroleptic malignant syndrome, nystagmus, Parkinson's-like symptoms, photophobia, priapism, QRS prolongation, urine discolouration, vision colour changes. Management: Activated charcoal or gastric lavage within 1 hr. Supportive therapy. Multiple dosing of activated charcoal may be useful; not dialysable.
Drug Interactions
Increased risk of extrapyramidal symptoms (EPS) with central acetylcholinesterase inhibitors. Reduced absorption with aluminium salts. Reduced efficacy of amphetamines; increased risk of psychotic symptoms with amphetamines. Reduced efficacy or excess anticholinergic effects with anticholinergics. Additive hypotensive effects with antihypertensives, trazodone. May inhibit effects of bromocriptine on serum prolactin levels. Additive sedative effects with CNS depressants. May diminish effects of epinephrine. May inhibit the antiparkinsonian effect of levodopa. May increase risk of EPS with metoclopramide. Increased risk of neurotoxicity with lithium (rare). Increased serum levels with sulfadoxime-pyrimethamine. Increased toxicity or altered response with TCAs. May increase serum levels of valproic acid.
Potentially Fatal: Increased risk of malignant arrhythmias with other QTc-prolonging agents.
Lab Interference
May cause false-positive results when testing for TCAs through the EMIT system.
Action
Description: Mesoridazine is a phenothiazine antipsychotic. It has a piperidine side-chain and is a metabolite of thioridazine. It acts by blocking postsynaptic CNS dopamine receptors.
Onset: 30 min to 1 hr.
Duration: 4-6 hr.
Pharmacokinetics:
Absorption: Tablet: Erratic; Liquid: More dependable. Peak serum concentrations in 2-4 hr.
Distribution: Widely distributed into body including breast milk. Protein-binding: 91-99%.
Metabolism: Hepatic.
Excretion: Mainly via urine; 24-48 hr (elimination half-life).
Storage
Intramuscular:
Store at 25°C (77°F).
Oral:
Tablet: Store at 25°C (77°F). Oral solution: Store below 25°C (77°F); protect from light.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mesoridazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in